Regeneron Pharmaceuticals REGN

$735.20 +0.39 (0.05%)

Valuation

Market cap: 75,652,368,000
Revenue TTM: $14,342,900,000
Net income TTM: $4,504,900,000
PE ratio: 19.46
Forward PE: 17.14
Profit margin: 31.41%
Debt to equity: 0.06

Trading

Volume: 613,900
Avg volume: 759,548
Day's range: $729.20 – $742.50
Shares out: 102,955,000
Stochastic %K: 10%
Beta: 0.16
Analysts: Strong Sell
Price target: $859.48

Price

Company profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Website: https://www.regeneron.com
Address: 777 Old Saw Mill River Road, Tarrytown, United States

Latest news

No headlines yet.

Stocktwits

KryptonResearch14 Oct 3, 9:58 AM

$REGN $SNY Sanofi is paying Regeneron 1 billion upfront for four long-acting antibodies meant to carry the franchise past Dupixent's patent cliff. The structure goes up to 8 billion total: 1 billion now, another 7 billion in milestones. The catch is timing. The lead asset (REGN20423, an IL-13 antibody for eczema) is still in Phase 1, and the other three don't reach the clinic until 2027. One level down, this is Sanofi buying the Dupixent sequel before it needs one. Dupixent protection starts lapsing in the early 2030s, so the 1 billion is a franchise-continuity premium on mostly preclinical assets. Costs and profits split 50/50, Regeneron runs R&D, Sanofi runs global sales. The deal also settles the 2024 lawsuit between the two. New Sanofi CEO Belen Garijo closed it in her first five months; her predecessor tried and failed to expand the alliance (per Barclays via Reuters).

0 replies

RunnerSignals Oct 1, 8:23 PM

wall street just changed its mind $REGN got an argus upgrade while dropping 3% $CW sits 39% below its target and nobody noticed. someone on the desk is quietly loading up https://stocksrunner.com/news/2026-10-01-wall-street-analyst-upgrades-to-watch

0 replies

Stekli27 Oct 1, 6:00 PM

$KOD $OTLK $REGN Eyes on the horizon. 👀OTLK is delayed, but there’s still some potential in the US. 😉

0 replies

quassarcapital Oct 1, 3:52 PM

$REGN (Regeneron) renews its partnership with Sanofi, which will pay $1.X billion upfront plus up to $7.X billion in milestones to develop next-generation antibodies as a successor to Dupixent, whose patent expires in 2031, led by REGN20423 in Phase 1 for atopic dermatitis.

0 replies

OpenOutcrier Oct 1, 12:33 PM

$REGN (+0.8% pre) $SNY Sanofi to invest up to $8BN to expand alliance with Regeneron https://ooc.bz/l/116185

0 replies

seven01trades Oct 1, 12:20 PM

$REGN $SNY — Confirmed $8B immunology expansion: Regeneron Pharmaceuticals and Sanofi expanded their long-running immunology partnership to cover four next-generation long-acting antibodies. Sanofi will pay Regeneron $1B upfront, with REGN eligible for up to another $7B in milestones. Future development/commercialization costs and profits will be shared 50/50. Sanofi One program, REGN20423, is already in Phase 1 for atopic dermatitis, with three additional antibodies expected to enter clinical trials in 2027. Importantly, the existing economics around blockbuster Dupixent remain unchanged. This is a substantial validation of Regeneron's next-generation immunology pipeline, not merely an early-stage research collaboration.

0 replies

StocktwitsNews Oct 1, 11:36 AM

Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights $REGN $SNY https://stocktwits.com/news/equity/markets/regeneron-sanofi-expand-immunology-alliance-with-1-b-upfront-payment-here-are-the-key-highlights/cZD0cNjRBiZ

0 replies

Stekli27 Oct 1, 9:33 AM

$KOD is gonna be the new $REGN. 👀

0 replies